We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

NervGen Pharma Corp (NGEN) NPV

Sell:2.96 CAD Buy:2.97 CAD Change: 0.035 CAD (1.20%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:2.96 CAD
Buy:2.97 CAD
Change: 0.035 CAD (1.20%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:2.96 CAD
Buy:2.97 CAD
Change: 0.035 CAD (1.20%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. The Company has two wholly owned subsidiaries, including NervGen US Inc. and NervGen Australia Pty Ltd.

Contact details

112-970 Burrard Street, Unit 1290
V6Z 2R4
+1 (778) 7311711

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
199.62 million CAD
Shares in issue:
70.04 million
Canadian Venture Exchange
Canadian dollars

Key personnel

  • Michael Kelly
    President, Chief Executive Officer, Director
  • William Adams
    Chief Financial Officer, Company Secretary
  • Daniel Mikol
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.